MoonLake Immunotherapeutics
MLTX
118 hedge funds and large institutions have $3.21B invested in MoonLake Immunotherapeutics in 2023 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 11 closing their positions.
327% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 11
42% more funds holding
Funds holding: 83 → 118 (+35)
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
12% more capital invested
Capital invested by funds: $2.86B → $3.21B (+$352M)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
23.14% less ownership
Funds ownership: 128.44% → 105.3% (-23%)
91% less call options, than puts
Call options by funds: $5.47M | Put options by funds: $61.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$32M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$21M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$20.8M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$16.2M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$37.3M |
| 2 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$32.6M |
| 3 |
AG
Artal Group
Luxembourg
|
-$20.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$20.2M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$18.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Alyeska Investment Group
Chicago,
Illinois
| – | -$2.92M | -57,347 | Closed |
|
|
E
127
Ergoteles
New York
| – | -$1.97M | -38,617 | Closed |
|
|
SC
128
Shay Capital
New York
| – | -$485K | -9,500 | Closed |
|
129
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$480K | -9,421 | Closed |
|
MLTX Hedge Fund Activity: Q3 2023 in Review
118 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2023, worth a combined $3.21B — up 12% from $2.86B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new MLTX positions and 11 closed out — a net gain of 36 holders — while 31 added to existing stakes and 26 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $32M. The largest seller was Polar Capital Holdings, cutting an estimated $37.3M.
- 118 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2023, up from 83 in Q2 2023.
- Funds reported $3.21B of MoonLake Immunotherapeutics stock for Q3 2023, up 12% quarter-over-quarter.
- 47 funds opened new MoonLake Immunotherapeutics positions in Q3 2023 and 11 closed out, a net change of +36 holders.
- The largest MoonLake Immunotherapeutics buyer in Q3 2023 was Adage Capital Partners, an estimated $32M added.
- The largest MoonLake Immunotherapeutics seller in Q3 2023 was Polar Capital Holdings, an estimated $37.3M sold.
Based on aggregated 13F filings for Q3 2023.